Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance

Eli Lilly And CoTrade
YieldMax Universe Fund of Option Income ETFsTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Eli Lilly And Co trades at $1,220.37 (market cap $1.08T), while YieldMax Universe Fund of Option Income ETFs trades at $7.63. The key difference: Eli Lilly And Co pays a 0.57% dividend while YieldMax Universe Fund of Option Income ETFs pays none. Which is the better fit depends on your goals.

LLYYMAX
Market Cap
$1.08T
Sector
HealthIncome / Options Overlay
52-Week High
$1.24K$13.26
52-Week Low
$639.43$7.27
Enterprise Value
$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

YieldMax Universe Fund of Option Income ETFs

YMAX trades at $7.635, down 0.97% on the day, with a bullish technical signal but bearish moving averages. The ETF shows a pattern of weekly dividend distributions, though recent payouts have decreased from $0.15 to $0.06, indicating potential income pressure. Key technical levels show support at $7 and resistance at $8, with RSI suggesting mild overbought conditions.

The outlook for YMAX hinges on its ability to sustain distributions amid cost concerns. Risks include the fund-of-funds fee structure and market volatility. Analyst sentiment is mixed, with some highlighting income appeal but cautioning on expense drag. Upside depends on stable option income generation in varying market regimes.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About YieldMax Universe Fund of Option Income ETFs

YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.

Read more on YMAX